Harvard Bioscience Inc (HBIO) is a publicly traded Healthcare sector company. As of July 28, 2026, HBIO trades at $6.06 with a market cap of $27.06M and a P/E ratio of -6.75. HBIO moved +1.19% today. Year to date, HBIO is -10.44%; over the trailing twelve months it is +6.07%. Its 52-week range spans $2.81 to $23.80. Rallies surfaces HBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
The average price target is $0.00.
| Metric | Value |
|---|---|
| Price | $6.06 |
| Market Cap | $27.06M |
| P/E Ratio | -6.75 |
| EPS | $-0.91 |
| Dividend Yield | 0.00% |
| 52-Week High | $23.80 |
| 52-Week Low | $2.81 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $85.53M |
| Net Income | $-9.78M |
| Gross Margin | 58.42% |
HBIO analyst coverage data. Average price target: $0.00.